RHY 0.00% 4.7¢ rhythm biosciences limited

US based company with better results launching world wide, page-64

  1. 556 Posts.
    lightbulb Created with Sketch. 86
    Why wouldn't it be intended as a replacement for current testing methodology?

    "GlycoKnow Colon is intended to be complementary to—and not a replacement for—current recommended colorectal cancer testing"
 
watchlist Created with Sketch. Add RHY (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.